Email this article FIVE-YEAR CANCER-SPECIFIC SURVIVAL OF STAGE III COLORECTAL CANCER PATIENTS
- Authors: Kokhnyuk V.Т.1
-
Affiliations:
- N.N. Alexandrov National Cancer Center of Belarus, Minsk
- Issue: Vol 2, No 4 (2013)
- Pages: 7-11
- Section: IN FOCUS
- Published: 01.03.2015
- URL: https://onco-surgery.info/jour/article/view/89
- DOI: https://doi.org/10.17650/2220-3478-2013-0-4-7-11
- ID: 89
Cite item
Full Text
Abstract
The paper presents long-term results of radical treatment for stage III colorectal cancer patients. The prognostic factors affecting cancer-specific survival (CSS) are analysed, and the impact of the devised technique of adjuvant chemotherapy (ACT) on CSS is evaluated.
Objective of the study: Enhancing the efficacy of stage III colorectal cancer treatment by devising and using a novel technique of ACT.
Materials and methods. The study enrolled 395 primary colorectal cancer patients. Radical treatment alone was administered to 203 patients, the remaining 192 patients (of 395) received adjuvant therapy supplementary to radical treatment.ACT was carried out according to the regimen we had devised: 30-minute intravenous infusion of calcium-folinate (leucovorin) at a dose of 200 mg/m2 immediately followed by 4-hour intravenous infusion of 5-fluorouracil at a dose of 400 mg/m2. The first course of chemotherapy was started on day 28–30 after radical surgery. The duration of each course was 5 days with 4-week intervals between them. A total of 4–6 chemotherapy courses was performed.
Conclusions .The proposed ACT regimen made it possible to improve 5-year CSS of stage III colorectal cancer patients from 51.1 ± 3.8 to 63.3 ± 4.9 % (p = 0.009).
About the authors
V. Т. Kokhnyuk
N.N. Alexandrov National Cancer Center of Belarus, Minsk
Author for correspondence.
Email: fake@neicon.ru
Belarus
References
Supplementary files
